1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
PharmaRoth Labs, Inc.

PharmaRoth Labs, Inc.

ROTH
PharmaRoth Labs, Inc.US flagOther OTC
0.00
USD
- -
- -
3,512.00Market Cap
PharmaRoth Labs, Inc.
ROTH
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
TTM
FRC
- -
- -
- -
- -
Revenue per Share
- -
- -
-0.01
- -
Basic EPS, GAAP
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
-0.01
- -
Tangible Book Value per Share
26
128
47
133
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-167.58
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-296.65
Profit Margin (%)
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
133
133
149
Market Capitalization
8
4
5

Working Capital

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
1,185.3%
Free Cash Flow
- -
- -
719.14%
Net Income, GAAP
- -
- -
1,950.61%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
-0.01
2011
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
Similar Companies
Concord Drugs Limited (CONCORD.BO)
Blueprint Medicines Corporation (0HOJ.L)
Sunil Healthcare Ltd. (SUNLOC.BO)
Patidar Buildcon Limited (PATIDAR.BO)
Adline Chem Lab Ltd. (ADLINE.BO)
InNexus Biotechnology, Inc. (IXSBF)
Business
PharmaRoth Labs, Inc. (ROTH) operates as a nutraceutical company focused on the prevention and treatment of type II diabetes worldwide; it produces, markets, and distributes Sucanon, a clinically-tested herbal-based nutraceutical treatment that functions as an insulin sensitizer to improve the body's utilization of insulin and normalize blood sugar levels without risking hypoglycemia. Founded in 2000 and headquartered at 8250 West Charleston Boulevard, Suite 120, Las Vegas, Nevada, the company holds intellectual property rights for Sucanon's production, marketing, and global distribution; it targets consumers managing type II diabetes through oral herbal therapies in the health technology and personal care products sectors. Formerly known as Fero Industries, Inc., the company changed its name to PharmaRoth Labs, Inc. in March 2013, marking its strategic shift to nutraceutical diabetes solutions; no major acquisitions, partnerships, funding rounds, or new product launches have been reported in the last 1-2 years, with recent financials reflecting modest revenue of approximately US$200,000 and ongoing operations under CEO Luis Manuel Lopez.